View Older Stories View More Recent Stories
-
Medtronic study shows diabetes system maintained glucose targets despite missed doses
-
William Blair Upgrades Medtronic, Inc. (MDT) to Outperform
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
Piper Sandler on Medtronic, Inc. (MDT): 'RDN Survey Indicates Momentum'
-
Citi Adjusts Large Cap Recommended List, Micron (MU) Removed
-
Increasing unusual call option volume: PM MDT RCL ZSL MO OMER LUV PBR AMBA RF COPX
-
Medtronic files for IPO of diabetes unit MiniMed
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
Nephron Upgrades Medtronic, Inc. (MDT) to Buy
-
Medtronic (MDT) Declares $0.71 Annual Dividend; 0.7% Yield
-
Medtronic's (MDT) HUGO Approval an Important, Positive Step - Stifel
-
Medtronic receives FDA clearance for Hugo robotic surgery system
-
Medtronic launches MiniMed 780G system with Abbott's Instinct sensor in US
-
Medtronic, Inc. (MDT) PT Raised to $110 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $102 at UBS Following Q2 Print
-
Medtronic, Inc. (MDT) PT Raised at RBC Capital on Growth Acceleration
-
Medtronic, Inc. (MDT) PT Raised to $111 at Bernstein Following 'Strong Q'
-
Medtronic, Inc. (MDT) PT Raised to Street High $125 at Mizuho
-
Medtronic, Inc. (MDT) PT Raised to $114 at Wells Fargo
-
Medtronic, Inc. (MDT) PT Raised to $120 at Leerink Partners
-
Medtronic, Inc. (MDT) PT Raised to $110 at Jefferies
-
Goldman Sachs Upgrades Medtronic, Inc. (MDT) to Neutral
-
Medtronic, Inc. (MDT) PT Raised to $117 at Citi
-
Medtronic, Inc. (MDT) PT Raised to $105 at Piper Sandler
-
Medtronic, Inc. (MDT) PT Raised to $115 at Evercore ISI
-
Medtronic beats Q2 expectations, raises full-year outlook
-
Medtronic (MDT) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
-
Medtronic (MDT) call put ratio 1 call to 1 put into quarter results
-
TD Cowen on Medtronic, Inc. (MDT): 'Buy; We Expect Solid F2Q Results'
-
Piper Sandler on Medtronic, Inc. (MDT): 'We Remain Cautious on the Outlook'
-
These stocks are latest additions to Mizuho's Top Picks list
-
Piper Sandler: 'Warming Up To Medtronic, Inc. (MDT) Story'
-
Bernstein SocGen Group Reiterates Outperform Rating on Medtronic, Inc. (MDT), can RDN be the biggest thing MDT ever does?
-
Increasing unusual call option volume: XLI XLB BYND WU RVPH CLOV MDT TMQ CLNE
-
Medtronic, Inc. (MDT) PT Raised to $105 at Stifel
-
Medtronic begins U.S. study of Hugo robotic surgery system for gynecology
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
Stifel: Electrophysiology Market Growth is Healthy
-
Piper Sandler on calls with diabetes clinicians
-
Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Orchestra BioMed presents data showing sustained blood pressure drops
-
Medtronic Hugo robot system meets hernia repair study endpoints
-
FDA clears Medtronic's MiniMed 780G system for type 2 diabetes use
-
Orchestra BioMed publishes clinical data on blood pressure therapy
-
TD Cowen Highlights 'Huge Growth Opportunity' for Medtronic, Inc. (MDT)
-
Wolfe Research Reiterates Peerperform Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $96 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $95 at UBS
-
TD Cowen on Medtronic, Inc. (MDT): 'Pullback Seems Excessive'
-
Medtronic, Inc. (MDT) PT Raised to $103 at RBC Capital

